Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions
about
Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort StudyTreatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.Chimeric SCID-hu Model as a Human Hematopoietic Stem Cell Host That Recapitulates the Effects of HIV-1 on Bone Marrow Progenitors in Infected Patients.Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak.Recent advances in the management of pruritus in chronic liver diseasesCase report of two cases of fever, rash, and organ involvement during the treatment of leprosyNovel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.Current development and future prospects in chemotherapy of tuberculosisExperience with rifabutin replacing rifampin in the treatment of tuberculosis.Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherenceNew drugs to treat tuberculosis.Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment.New drugs and regimens for treatment of TB.Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.Challenges and opportunities in developing novel drugs for TB.Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents.Pathogenesis and management of pruritus in cholestatic liver disease.Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future.Rifabutin: where do we stand in 2016?Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis?Antituberculosis Drug-Induced Liver Injury with Autoimmune Features: Facing Diagnostic and Treatment ChallengesNot all adverse drug reactions originate from active component: coloring agent-induced skin eruption in a patient treated with rifampicin.Rifampicin-Induced Fever in a Patient with Brucellosis: A Case Report.Controversies in the Management of Cutaneous Adverse Drug Reactions.
P2860
Q28547335-C3A9D37F-7218-461B-B5E9-607C6A420237Q30383012-711D6ED0-17DC-4BC8-94F7-A941641C4956Q33165650-36BFC57F-8CB2-413B-B5B4-82B14C375BC5Q33382126-12FD1E40-C1DB-4CD0-A21E-E7B1791C56B8Q33396678-627D133D-3D0B-4A65-9097-80F78ABCE86FQ33719935-2D043F14-6576-41E1-9E82-369176D13D7AQ35233547-7BD548D1-EA37-422C-B2B7-8A27E4C03E3AQ35607718-D480D38E-AA40-4452-8777-8DFD78A6F942Q35657599-EB8F1BBB-DC0A-4A63-95F9-20ACC21ADFA0Q35705874-CB9F1D29-E0BA-40AE-B7AF-419155F03EACQ35789741-F73F7F17-7D4F-43EF-8D2C-71D13105D35FQ35954014-A0ED7A56-427C-47E3-B2F9-5B8FD1739B7FQ36018409-4322AFEB-669A-4265-AA6C-5A77AF9D349CQ36082913-880DB764-7CA5-4834-A351-F72FAEC4A6D3Q36825354-4ED1BE71-4AC0-4540-9F76-80828914BB6CQ36949454-2E2FAACD-5C3F-4AD4-B422-99AD3660DC57Q37613267-35A523E0-C262-4E08-B874-A3EE664B7AEFQ37924294-B279C21F-2EF0-46DB-8199-76ADDEAFBC0CQ37991389-A7D3239A-09A4-4312-8C01-A619BE528401Q37993126-D8075A77-1C60-4176-AF93-042FE472740DQ38003494-61BF45F2-04DB-459F-A5E9-1F510FDAE72BQ38786540-FB243961-816D-4B22-9B30-C7E440E12CA5Q40130432-07097C93-93D0-440C-920C-B9F2C3005025Q40367327-358FEBDC-049D-450B-8BEF-614EFEC3D112Q44596953-0008B872-02B5-4599-9CEF-46FEE0EA1A33Q50038546-432C4B9A-368C-4E45-9894-0447C14ED4C5Q55261128-6A614B6B-B663-41ED-996A-5A85798337AD
P2860
Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@ast
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@en
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@nl
type
label
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@ast
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@en
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@nl
prefLabel
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@ast
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@en
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@nl
P2093
P1433
P1476
Hypersensitivity reactions to ...... he anaphylactic-like reactions
@en
P2093
P356
10.1097/00005792-199911000-00001
P407
P577
1999-11-01T00:00:00Z